TriangleHEALTH PROFESSIONAL · SOURCE READING
Classical Hodgkin lymphoma, high-risk disease
Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 16, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Table 9 summarizes the results of treatment approaches used for pediatric patients with high-risk Hodgkin lymphoma.
Source links and citations
| Chemotherapy (No. of Cycles)a | Radiation (Gy) | Stage | No. of Patients | Event-Free Survival Rate (No. of Years of Follow-up) | Survival Rate (No. of Years of Follow-up) |
|---|---|---|---|---|---|
| E = extralymphatic; IFRT = involved-field radiation therapy; ISRT = involved-site radiation therapy; N/A = not applicable; No. = number; PFS = progression-free survival. | |||||
| aFor more information about the chemotherapy regimens, see Table 6. | |||||
| OEPA (2) + COPDAC (4) [22] | IFRT (20–35) | IIEB, IIIEA/B, IIIB, IVA/B | 239 | 86.9% (5) | 94.9% (5) |
| ABVE-PC (3-5) [21,79] | IFRT (21) | IIB, IIIB, IV | 163 | 85% (5) | 95% (5) |
| AEPA (2); CAPDAC (4) [63] | Individual residual nodal (25.5) | IIB, IIIB, IV | 77 | 97.4% (3) | 98.7% (3) |
| Bv-AVE-PC (5) [53] | ISRT | IIB + Bulk, IIIB, IV | 587 | 92.1% (3) | 99.3% (3) |
| N-AVD (6) [30] | None | III, IV | 487 total (118 aged 12–17 y) | PFS: 92% (2) | 99% (2) |
Continue within this section
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice